HighRes, Novo Nordisk work on robotic drug discovery

January 24, 2020 -- Life science robotics company HighRes Biosolutions and global healthcare company Novo Nordisk plan to design a robotic platform for high-throughput biologics engineering and characterization of potential drug discovery candidates.

The multisystem robotics platform will accelerate discovery of potential candidates for Novo Nordisk's peptide and large molecule therapeutics research, according to the company.

The platform will include automated and integrated cells for production, characterization, and functional analysis of thousands of biologic compounds every month. Also, it aims to cover the full range from small synthetic peptides to recombinantly expressed large proteins, and it will include chemical modification of the molecules.

Small-molecule chaperones may reverse Alzheimer's symptoms in mice
A novel treatment for Alzheimer's disease involving the administration of pharmacological chaperones that prevent amyloid beta and tau tangles from forming...
Researchers identify microproteins with major implications in disease
A new study published in Nature Communications on October 25 provides evidence of how microproteins contribute to cellular stress. Researchers...
The drug development industry is hungry for 3D printing – from the 4th Peptide Drug Design & Delivery Summit
The Science Advisory Board attended the 4th Annual Peptide Drug Design and Delivery Summit in Philadelphia from August 27 to 29. One of the most discussed...

Copyright © 2020 scienceboard.net

Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter